Gilead Sciences, Inc. $GILD Shares Purchased by Trilogy Capital Inc.

Trilogy Capital Inc. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 31.3% in the 2nd quarter, Holdings Channel reports. The fund owned 41,026 shares of the biopharmaceutical company’s stock after buying an additional 9,777 shares during the period. Trilogy Capital Inc.’s holdings in Gilead Sciences were worth $5,183,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of the stock. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC lifted its stake in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC purchased a new stake in Gilead Sciences during the fourth quarter worth $26,000. Wealth Preservation Advisors LLC boosted its holdings in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the fourth quarter valued at $28,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $131.15 on Tuesday. The business has a 50 day moving average price of $129.55 and a 200 day moving average price of $136.03. The company has a market capitalization of $162.83 billion, a P/E ratio of 17.87 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the prior year, the company earned $1.81 earnings per share. Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.78 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00. Following the sale, the chief executive officer directly owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. This represents a 2.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 67,000 shares of company stock worth $8,687,140 in the last three months. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on GILD. The Goldman Sachs Group increased their target price on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Weiss Ratings lowered Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Morgan Stanley cut their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research report on Monday, July 27th. Royal Bank Of Canada reduced their target price on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Finally, Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $157.93.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.